Articles by The Wall Street Analyzer

About The Wall Street Analyzer
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.
Consumer

The commercial real estate market is wobbling, and 2 of the largest players are feeling the pain of higher rates and tighter credit

April 24, 2023 The Wall Street Analyzer Comments Off on The commercial real estate market is wobbling, and 2 of the largest players are feeling the pain of higher rates and tighter credit

Jennifer Sor Sun, April 23, 2023, 4:45 PM EDT Commercial real estate is feeling the pain of higher rates and tighter credit conditions. Blackstone reported big losses in the past quarter, and Brookfield reportedly defaulted […]

No Picture
Market News

Why Cigarette Maker Philip Morris International Stock Is Plunging Today

April 20, 2023 The Wall Street Analyzer Comments Off on Why Cigarette Maker Philip Morris International Stock Is Plunging Today

Shivani Kumaresan Thu, April 20, 2023, 12:42 PM EDTIn this article:  PM-4.99%WatchlistWatchlistSignificant Event | 1dPhilip Morris International Reports Quarterly Net Revenue Of $8,019 Million Versus $7,746 Million Reported Last Year Philip Morris International Inc (NYSE: PM) reported a first-quarter FY23 […]

No Picture
CEO Interviews

Safe Harbor Financial (NASDAQ: SHFS)

April 19, 2023 The Wall Street Analyzer Comments Off on Safe Harbor Financial (NASDAQ: SHFS)

ABOUT: Safe Harbor is among the first service providers to offer compliance, monitoring and validation services to financial institutions, providing access to traditional banking services to cannabis, hemp, CBD, and ancillary operators, making communities safer, […]

CEO Interviews

Inhibikase Therapeutics, Inc. (Nasdaq: IKT)

April 19, 2023 The Wall Street Analyzer Comments Off on Inhibikase Therapeutics, Inc. (Nasdaq: IKT)

ABOUT: Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson […]